A Randomized Phase Ib/II Study of the Selective Small Molecule Axl Inhibitor Bemcentinib (BGB324) in Combination with Either Dabrafenib/trametinib (D/T) or Pembrolizumab in Patients with Metastatic Melanoma
ANNALS OF ONCOLOGY（2023）
关键词
Tumor Regression
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要